Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy (NASDAQ:SRPT)
champja In my last Sarepta Therapeutics (NASDAQ:SRPT) article, I discussed Sarepta’s Q3 performance and their clinical progress in Duchenne muscular dystrophy (DMD) and other rare diseases. At that time, Sarepta had recently revealed their Q3 product revenue was up 49% year-over-year, aided by ELEVIDYS, which pulled in $69.1M in its first quarter on the market….